MARKSANS Marksans Pharma Q1 FY26 results (Apr–Jun 2025) and concall
Marksans Pharma reported a seasonally soft Q1 FY26 with operating revenue growing 5% YoY to INR620 crores, primarily driven by strong US market performance. However, profitability was impacted by high single-digit price erosion in the UK, increased employee expenses, and one-time provisions, leading to a 560 bps decline in EBITDA margin to 16.1% and a 34.7% drop in PAT. The company is focusing on strategic product launches and operational efficiencies to navigate market uncertainties and improve future performance, with early signs of demand recovery in Q2.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 309 | 312 | 299 | 320 |
| EBITDA | 63 | 60 | 52 | 70 |
| Net profit | 63 | 55 | 38 | 48 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
